Full-Time

Senior Director

Compound Development Team Leader, Neuropsychiatry

Posted on 11/23/2025

Deadline 11/30/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Cambridge, MA, USA + 1 more

More locations: New Hope, PA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Word/Pages/Docs
Risk Management
Excel/Numbers/Sheets
Requirements
  • A minimum of ten years of pharmaceutical industry or related experience overall and/or a minimum of five to seven years of drug development or related experience
  • Experience in a leadership role within a multi-functional Research and Development organization
  • Ability to integrate all cross functional disciplines into a successful strategy and project plan
  • Understanding of requirements for successful commercialization of a new product
  • Expert knowledge of the drug development process and the competitive environment
  • Strong problem solving skills for developing creative solutions and meeting project objectives
  • Demonstrated influence, negotiation and conflict resolution skills, including the ability to influence without clear reporting authority
  • Significant work experience in a leadership position in a team matrix environment
  • Strong planning and tracking skills
  • Demonstrated ability of strategic thinking and contingency planning with respect for Johnson & Johnson Innovative Medicine objectives
  • Fluent in written and spoken English
  • Working knowledge of the use of Microsoft suite of software products including Excel and Word
  • Experience and knowledge of Good Clinical Practices and regulatory requirements for the conduct of clinical trials and for the appropriate contributions to regulatory filings
  • Advanced Degree (Ph.D., M.D., M.B.A.) highly desirable
Responsibilities
  • Matrix Leader of Cross-functional Compound Development Team; Works with TA Leadership Team to develop compound strategy
  • Leads the development and maintenance of the program plan and decision-making by providing relevant research, analysis, and expertise
  • Manages successful cross-functional execution of the project plan through negotiating with Function heads about functional deliverables
  • Aligns the CDT to achieve its goals through the networks of people/functions represented on the team
  • Identifies critical risks and assumptions and transparently communicate them to the CDT, functions, TA & Pharma governance committees, and senior management
  • Identifies issues and leads contingency planning
  • Leads resolution of issues at the CDT, TA & Pharma governance committees and senior management levels
  • Leads CDT problem-solving and provide decision-making tools and techniques
  • Leads the communication of strategy and plans to the TA & Pharma governance committees, development partners, and other key stakeholders
  • Responsible for review of medical publications emerging from the Team and its affiliates
  • Accountable for the budget for the compound or program
  • Works with Function heads to: Select CDT members; Set Goals and Objectives for CDT members; Mentor and guide CDT members; Provide input for performance evaluation of CDT members
  • Execute the program and manage deliverables & financials
  • May act, in concert with senior clinical personnel, as a company spokesperson regarding publication of clinical research findings and presentations to relevant health authorities (e.g. global health authority meeting related to NDA/MAA/BLA)
  • Develop credible relationships with scientific leaders, key regulatory officials
Desired Qualifications
  • Clinical Evaluations
  • Clinical Trial Protocols
  • Consulting
  • Cross-Functional Collaboration
  • Design Mindset
  • Drug Discovery Development
  • Entrepreneurship
  • Good Clinical Practice (GCP)
  • Lateral Leadership
  • Medicines and Device Development and Regulation
  • Program Management
  • Regulatory Affairs Management
  • Relationship Building
  • Safety-Oriented
  • Scientific Research
  • Strategic Change
  • Study Management

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Icotyde launches with 1,500 prescriptions, Guggenheim projects $14.9 billion peak sales.
  • Atraverse Medical acquisition bolsters HOTWIRE system for atrial fibrillation ablations.
  • ETHICON 4000 Stapler gains CE Mark, reducing surgical leaks costing €5,200 per case.

What critics are saying

  • Stelara sales plummet 60% to $656 million from Amgen and Samsung biosimilars.
  • Over 90,000 talc lawsuits trigger $966 million October 2025 verdict against J&J.
  • CARVYKTI manufacturing shortfalls cap multiple myeloma sales growth in 2026.

What makes Johnson & Johnson unique

  • Diversified revenue spans Innovative Medicine, MedTech, and consumer health segments.
  • DARZALEX sales hit $4 billion in Q1 2026, exceeding forecasts by $600 million.
  • CARTO System marks 30 years, powering AI-driven CARTOSOUND SONATA for electrophysiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE